Datopotamab deruxtecan, an ADC directed against Trop-2, was investigated in the phase 1 TROPION-PanTumor01 trial in patients with advanced NSCLC with an actionable mutation (including EGFR) who had previously progressed after treatment with a TKI and chemotherapy [117]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.